Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 72162-2212

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 72162-2212). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Clopidogrel Fig)

Figure 1 shows the exposure to Clopidogrel Active Metabolite following multiple doses of Clopidogrel 75 mg alone or with Proton Pump Inhibitors (PPIs). The table displays the effect of co-administered PPIs on the active metabolite AUC (area under the curve), along with the mean and 90% confidence interval. The PPIs mentioned include Deslansoprazole (60 mg), Lansoprszole (0 mg), Pantoprazole (80 mg), and Omeprazole (80 mg). It also indicates the change relative to Clopidogrel administered alone.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

This text appears to be a description of a clinical study evaluating the occurrence of cardiovascular death, myocardial infarction, and stroke in patients receiving different treatments. The treatments being compared are a placebo with aspirin and clopidogrel with aspirin. The cumulative event rate is presented, and the data suggests a statistically significant difference with a p-value of 0.00009. The study followed patients for a period of 12 months and mentions the use of other standard therapies alongside the tested treatments.*

FDA Label Image

Figure3 (Clopidogrel Fig3)

FDA Label Image

Figure4 (Clopidogrel Fig4)

This is a description of the results from the COMMIT Study, which evaluated the effects of a medication called Clopidogrel on death rates. The study compared the death rates of patients who received the placebo (1845 deaths, 8.1%) versus those who received Clopidogrel (1726 deaths, 7.5%). The results showed a 7% proportional risk reduction in death rates with Clopidogrel compared to the placebo, with a p-value of 0.03. The study followed patients for up to 28 days after randomization, and all treated patients received aspirin.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

This text appears to be providing information about a comparison between two treatments, Placebo and Clopidogrel. It mentions the number of events and the percentage of patients experiencing those events in each group. The text also mentions a 9% proportional risk and indicates a reduction in deaths with a p-value of 0.002. Additionally, there is mention of re-infarction or stroke occurring before the first discharge, and a timeline ranging from 7 to 28 days since randomization.*

FDA Label Image

Figure6 (Clopidogrel Fig6)

FDA Label Image

Figure7 (Clopidogrel Fig7)

FDA Label Image

Figure8 (Clopidogrel Fig8)

FDA Label Image

Structure (Clopidogrel Str)

FDA Label Image

Label (Lbl721622212)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.